ivermectin - versus control - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.91 [0.53, 1.57]< 10%3 studies (3/-)63.4 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.88 [0.69, 1.13]< 10%2 studies (2/-)83.7 %some concernnot evaluable moderateimportant-
clinical improvement 1.07 [0.87, 1.32]> 10%1 study (1/-)73.8 %some concernnot evaluable moderateimportant-
clinical improvement (21-day) 1.28 [0.79, 2.10]> 10%1 study (1/-)84.1 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.07 [0.87, 1.32]> 10%1 study (1/-)73.8 %some concernnot evaluable moderateimportant-
hospitalization 0.79 [0.57, 1.10]< 15%3 studies (3/-)91.8 %some concernnot evaluable moderateimportant-
mechanical ventilation 1.34 [0.30, 6.03]< 10%1 study (1/-)35.2 %lownot evaluable highimportant-
Recovery (time to event analysis only) 0.79 [0.42, 1.48]> 10%1 study (1/-)23.0 %some concernnot evaluable moderateimportant-
viral clearance 0.92 [0.77, 1.09]> 10%1 study (1/-)17.3 %lownot evaluable highimportant-
viral clearance by day 14 0.76 [0.45, 1.28]> 10%1 study (1/-)15.0 %lownot evaluable highimportant-
viral clearance by day 7 0.93 [0.79, 1.09]> 10%2 studies (2/-)18.5 %lownot evaluable highimportant-

safety endpoints 00

serious adverse events 1.00 [0.14, 7.17]< 10%1 study (1/-)50.0 %some concernnot evaluable moderateimportant-
adverse events 1.00 [0.20, 5.07]< 10%1 study (1/-)50.0 %lownot evaluable highnon important-
hyperbilirubinemia 0.66 [0.33, 1.30]< 10%1 study (1/-)88.4 %lownot evaluable highnon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.